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Abstract 
Diarrhoeal diseases in children under five years are the second leading 
cause of deaths in children worldwide, and especially in low-income 
countries in sub-Saharan Africa and in southern Asia where about 
450,000 children die every year as a result of diarrhoea. The main cause 
of diarrhoeal diseases is acute gastroenteritis that is due to infection with 
viruses, bacteria or protozoa, most often acquired by ingestion of con-
taminated water or food, or through contact between persons. Studies 
of acute gastroenteritis in children in low-income countries have identi-
fied rotavirus, norovirus, Cryptosporidium, enterotoxigenic Escherichia coli 
and Shigella as the most frequent aetiologies to diarrhoea. Rotavirus has 
been the cause of more than half of all deaths caused by diarrhoea in 
children, but its impact is declining due to increased use of the rotavirus 
vaccines Rotarix and RotaTeq. 
Enteric infections are frequent in small children in low-income 
countries, both in those with diarrhoea and in healthy controls, and 
often two or more pathogens are present at the same time. How co-
infecting pathogens are associated, and if multiple infections aggravate 
symptoms, is not well known. We investigated polymicrobial infections 
among 1318 children in Rwanda and Zanzibar and found negative 
associations between the agents that alone are capable of causing 
diarrhoea. Positive associations between agents only in the patient 
group were unusual and rarely aggravated the symptoms. Positive 
associations in both patients and controls were found between two pairs 
of targets, and these results were useful for estimating the proportion of 
Escherichia coli that carried both or only either of some important 
virulence factors (ST or LT; eae or bfpA). 
Clearance and acquisition of enteric pathogens were studied in 127 
children in Zanzibar with diarrhoea. Faeces samples were collected on 
admission and at a follow-up 14 days later. The majority of the patho-
gens detected at baseline had been eradicated or decreased in amount 
on follow-up, but in parallel new infections occurred at a high rate. The 
clearance rates were independent of the children's nutritional status. The 
findings suggest that the high rates of enteric infections in children in 
low-income settings depend on living conditions with high exposure 
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rather than failure to eradicate pathogens because of malnutrition and 
poor immune responses. 
Rotavirus vaccines were introduced in Rwanda in May 2012. Analysis 
of samples from children with diarrhoea during the pre- and post-
vaccine period showed a significantly lower rate of rotavirus in vaccin-
ated children less than one year of age compared with unvaccinated 
children in the same age group, as presented in Paper IV. In children 
aged 1–5 years the rate of rotavirus was independent on vaccination 
status. Severe dehydration was more rare in vaccinated children, inde-
pendently of age. 
To allow simple distinction between rotavirus genotypes in large 
numbers of samples, we developed a multiple real-time PCR method. 
This assay was used for genotyping of rotavirus in samples from 
Sweden (n = 775) and Rwanda (n = 549). In Sweden, where vaccination 
has not yet been implemented, the predominant rotavirus genotype in 
patients with diarrhoea changed significantly over time during 2010–
2014, and these shifts differed also between age groups. Likewise, in 
Rwanda there were significant genotype shifts during 2009–2015, i.e. 
both before and after the introduction of vaccination. These results 
indicate that changes in genotype frequencies observed after the start of 
vaccination most likely were part of natural fluctuations rather than 
reflecting that the vaccine induced poorer protection against certain 
genotypes.  
In summary, this work provides new knowledge on the importance 
of enteric co-infections and shows that children in poor settings are 
heavily exposed to enteric pathogens that they effectively clear. By the 
introduction of a new and simple rotavirus genotyping method we show 
how rotavirus genotypes change extensively over time in both Sweden 
and Rwanda, irrespective of vaccination. Furthermore, the results 
demonstrate that the introduction of rotavirus vaccination in Rwanda in 
2012 has reduced the number of rotavirus infection in children below, 
but not above, the age of 12 months. Finally, vaccination has reduced 
the proportion of rotavirus infections that cause severe dehydration, but 
resulted in a relative increase of other viruses detected in children with 
diarrhoea. 
Keywords:	 gastroenteritis, diarrhoea, children, co-infections, aetiology, 
real-time PCR, follow-up, rotavirus, genotypes, vaccine 
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Sammanfattning    
Diarrésjukdomar hos barn under fem år är den näst vanligaste orsaken 
till dödsfall hos barn världen över, och framför allt i låginkomstländer 
söder om Sahara i Afrika och i södra Asien där ca 450 000 barn årligen 
dör till följd av diarré. Majoriteten av diarrésjukdomarna orsakas av akut 
gastroenterit till följd av infektion av patogener. Akut gastroenterit kan 
orsakas av virus, bakterier eller protozoer och sprids främst via konta-
minerat vatten eller mat samt genom kontaktsmitta mellan personer. 
Studier av akut gastroenterit hos barn i låginkomstländer har identifierat 
rotavirus, norovirus, Cryptosporidium, ETEC och Shigella som de patoge-
ner som är starkast associerade med diarré. Rotavirus, som bedömts 
orsaka närmare hälften av alla dödsfall till följd av diarré, är sannolikt 
den viktigaste patogena mikroorganismen bland dessa. Det finns idag 
två godkända vacciner mot rotavirus, Rotarix och RotaTeq.  
Enteriska patogener påvisas ofta hos barn i låginkomstländer, både 
hos dem med diarré och hos friska kontroller, och ofta förekommer två 
eller flera patogener samtidigt. Hur patogener är associerade till 
varandra och om multipla infektioner påverkar graden av symptom är 
relativt okänt. I delarbete I i avhandlingen studerades associationer 
mellan olika patogener hos barn i Rwanda och på Zanzibar med 
polymikrobiella infektioner. Vi fann en negativ association mellan de 
agens som var för sig är starkt associerade till sjukdom. Positiva 
associationer mellan agens var ovanliga och samverkade sällan till att 
förvärra symtomen.  
I delarbete II studerades utläkning och ny infektion av enteriska 
patogener hos barn på Zanzibar med diarré. Faecesprov togs vid sjuk-
domsdebut samt vid ett uppföljningstillfälle 14 dagar senare. Majoriteten 
av de patogener som detekterades vid sjukdomsdebuten var utläkta eller 
hade minskat i koncentration vid uppföljning, men nya infektioner före-
kom med hög frekvens. Fynden tyder på att den höga frekvensen 
tarmpatogener hos barn i låginkomstländer snarare beror på levnadsför-
hållanden med hög exponering än att de skulle vara långtidsbärare av 
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patogener på grund av undernäring och dåligt fungerande immun-
försvar. 
Rotavirusvaccin introducerades i Rwanda i maj 2012. Analys av prov 
från barn med diarré under tidsperioden före och efter vaccinin-
troduktion visade en signifikant lägre frekvens av rotavirus i vaccinerade 
barn under 1 år jämfört med ovaccinerade barn i samma åldersgrupp, 
vilket presenteras i delarbete IV. Hos äldre barn (1–5 år) var frekvensen 
av rotavirus oförändrad. Allvarlig uttorkning var ovanligare hos 
vaccinerade barn med rotavirusinfektion jämfört med ovaccinerade 
barnen med rotavirusinfektion.  
För att möjliggöra enkel identifiering av olika varianter av rotavirus, 
s.k. genotyper, i ett stort antal prover utvecklade vi en realtids-PCR 
metod, som presenteras i Delarbete III. Denna metod användes för 
genotypning av rotavirus i prov från Sverige (n = 775, Delarbete III) 
och Rwanda (n = 549, Delarbete IV). I Sverige, där vaccination ännu 
inte har införts, förändrades den dominerande rotavirusgenotypen hos 
patienter med diarré betydligt över tiden under 2010–2014, och dessa 
förändringar skilde sig mellan olika åldersgrupper. Även i Rwanda 
förändrades genotyperna påtagligt under 2009–2015, alltså både före 
och efter införandet av vaccination. Dessa resultat indikerar att de 
förändringar som sågs efter vaccinationsstart i Rwanda sannolikt var en 
del av naturliga fluktuationer snarare än ett tecken på att vaccinet 
inducerar ett sämre skydd mot vissa genotyper. 
Sammanfattningsvis ger detta arbete ny kunskap om betydelsen av 
enteriska saminfektioner och visar att barn i socioekonomiskt utsatta 
områden är starkt exponerade för tarmpatogener som de dock effektivt 
klarar av att bekämpa. Vidare introduceras en ny och enkel rotavirus-
genotypningsmetod som visar hur rotavirusgenotyper påtagligt för-
ändras över tid i både Sverige och Rwanda oberoende av vaccination. 
Våra resultat visar att introduktionen av rotavirusvaccinering i Rwanda 
år 2012 har minskat antalet rotavirusinfektioner hos barn under, men 
inte över, 1 års ålder. Vaccinationen minskade andelen rotavirus-
infektioner som orsakar svår uttorkning, men resulterade i en relativ 
ökning av andra sjukdomsorsakande virus hos barn med diarré. 
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1. Introduction 
Despite a considerable decline, diarrheal disease in children younger 
than 5 years still causes an estimated 690 million cases of illness and 
500,000 deaths every year worldwide. Sub-Saharan Africa and South 
Asia are most affected and about 90% of deaths occur there (Figure 1) 
[1,2].  The leading risk factors for diarrhoea are unsafe water, inadequate 
sanitation and malnutrition [3,4] and the main cause of diarrheal disease 
is acute gastroenteritis caused by enteric pathogens. This thesis investi-
gates enteric pathogens in samples collected from children less than 5 
years in two East African sites, Rwanda and Zanzibar. 
 
 
	
Figure 1. Worldwide distribution of diarrhoea associated                                  
deaths in children less than 5 years of age [5]. 
 
Rwanda is a small country, with a young population; 43% of 11.8 
million citizens are below 15 years of age. The access to improved 
drinking water sources, meaning protected springs, public taps/stand-
pipes or running water in dwelling and to improved sanitation, defined 
as unshared toilet facility or pit latrine with a slab, reaches 73% respec-
tively 54% of the inhabitants. Severe malnutrition is rare (0.7%) and the 
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proportion of children under five with underweight is 9.3%. In the last 
decade the mortality rate due to diarrhoea has been reduced with 48%, 
but 50 out of 1000 children still die before 5 years of age, and 9% of 
these deaths are caused by diarrhoea [5,6].  
 
In Zanzibar, a Tanzanian island with 1.3 million citizens, 98% have 
access to improved drinking water and 59% have improved, not shared 
sanitation facilities. On the other hand, 17% on the rural Zanzibar 
population have no facility at all available, the highest percentage in 
Tanzania. Underweight is present in 14% and malnutrition in 5% of 
children below five years of age. The mortality is 56 per 1000 children 
under five in Tanzania, of which 6% is due to diarrhoea, as compared 
with 29% 10 years ago [5,7]. 
 
A wide range of pathogens can cause acute gastroenteritis, including 
viruses (rotavirus, norovirus, astrovirus, sapovirus, adenovirus), bacteria 
(Shigella, Escherichia coli, Campylobacter, Salmonella, Vibrio cholerae, Yersinia 
enterocolitica, Aeromonas), and protozoa (Cryptosporidium, Entamoeba 
histolytica, Giardia intestinalis). In high-income countries, viruses are the 
major cause of acute infectious diseases, whereas in addition bacteria, in 
particular Escherichia coli and Shigella, are common in low-income coun-
tries.  
 
We have previously reported causes of gastroenteritis among children in 
Rwanda and Zanzibar [8-10]. Pathogens that may cause diarrhoea were 
identified in a large proportion of children with diarrhoea (>90%), but 
also among those without diarrhoea (>70%). The importance of the 
pathogens was investigated by comparing sick and healthy children, and 
by comparing children with mild or severe diarrhoea. By these compar-
isons rotavirus, enterotoxigenic Escherichia coli producing heat-stable 
toxin (ETEC-estA), Shigella, Cryptosporidium and norovirus genogroup II 
(GII) were identified as the most important causes of diarrhoea.  
 
These results agree well with a global enteric multi-center study (GEMS) 
conducted in 2007–2011 in sub-Saharan Africa and in south Asia, which 
showed that rotavirus, ETEC-estA and Shigella were the major causes of 
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childhood diarrhoea [11]. Additional analyses showed that also adeno-
virus 40/41 and Cryptosporidium were important causative agents [12]. 
New data presented from the Global Burden of Disease collaboration 
(GBD) emphasizes the importance of rotavirus, Cryptosporidium and 
Shigella as responsible for death in children under five years of age [5], 
and in addition The Global Rotavirus Surveillance Network identified 
Norovirus GII,  ETEC-estA and adenovirus 40/41 to be a major cause 
of acute watery diarrhoea worldwide [13].  
1.1 Rotavirus 
Rotavirus is a non-enveloped double stranded ribonucleic acid (RNA) 
virus in the reoviridae family. The virus is transmitted by faecal-oral 
route and after a short incubation (1-3 days), symptoms start, typically 
as nausea and vomiting, often with low-grade fever, followed by 
diarrhoea [14]. Dehydration is a frequent complication of the infection, 
especially in low-income countries where severe dehydration in small 
children can be fatal. Globally, death caused by rotavirus has decreased 
markedly the last decade, but still approximately 215,000 children die 
every year, the majority of them in low-income countries [15]. In high-
income countries, deaths due to rotavirus are rare and instead rotavirus 
infections are a socioeconomical problem.  
1.1.1 Rotavirus classification 
The genome of rotavirus is divided in 11 segments, each encoding for at 
least one structural protein (VP1, VP2, VP3, VP4 (VP5+VP8), VP6 and 
VP7) (Figure 2) or a non-structural protein (NSP1, NSP2, NSP3, NSP4, 
and NSP5). Rotaviruses are classified according to their antigenic speci-
ficities into serogroups and serotypes. There are seven serogroups of 
rotavirus, referred to as A through G. Humans are infected by 
serogroups A, B and C, with serogroup A causing more than 90% of 
the infections.  
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The VP4 and VP7 genes are important because their sequence varia-
bility defines the serotypes of rotavirus A. The surface protein VP4, 
protrudes as a spike (Figure 2), which binds to receptors on cells in the 
upper part of the small intestine and drives the entry into the cell. The 
virus becomes infectious when the endogenous enzyme trypsin, 
modifies VP4 to VP5 and VP8. The glycoprotein VP7 forms the outer 
surface and is, along with VP4, critical for inducing immunity to the 
infection. VP7 defines G-types, and the VP4 protein defines P-types of 
the virus [14]. Although all 11 genomic segments need to be taken in to 
account for complete classification, the genotype of the virus is usually 
defined by a combination of G-and P-types. There are 11 known G-
types and 13 P-types that infects humans [16-18].  
 
 
Figure 2. Rotavirus structural proteins and double-stranded (ds) RNA. 
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Because the genes coding for proteins G and P are present on different 
segments, reassortment may occur when two rotavirus strains within the 
same serogroup infect the same cell, creating strains with new P-G com-
binations. Today, at least 73 G/P genotype combinations of rotavirus 
serogroup A have been described to infect humans [19]. The five P-G 
combinations G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8] are 
considered to cause more than 75 % of rotavirus diarrhoea among 
children worldwide [17,18,20]. Additionally, G12P[8] and also G12P[6], 
has become frequently detected in recent years, flagged as emerging in 
in several countries, and proposed to be grouped among the most 
common genotypes [21-23].    
1.1.2 Pathogenesis and Immunity 
Rotavirus infects mature enterocytes in the mid and upper part of the 
villi of the small intestine. Viral replication leads to increased intra-
cellular Ca2+ level, increased secretion of Cl– and shut-off of the host 
cell protein synthesis. The viral protein NSP4 has endotoxin effects and 
activates the enteric nervous system, leading to the induction of intes-
tinal water and electrolyte secretion. Impaired hydrolysis of carbo-
hydrates may also contribute to excessive fluid loss from the intestine, 
and destruction of epithelium and villus ischemia may aggravate symp-
toms [14,24]. Rotavirus also has the ability to infect enterochromaffine 
cells in the gut and activates vagal afferent nerves, which through release 
of serotonin can stimulate brain stem structures and cause vomiting 
production[25]. 
 
The human immune response to rotavirus is not completely under-
stood, partly because much of knowledge about protection against rota-
virus is based on animal models, with a gut physiology that may not be 
representative for humans [26]. Primary rotavirus infection results 
almost exclusively in acute gastroenteritis, and induces immunity that 
protects against subsequent rotavirus infections. In otherwise healthy 
children, severe disease normally doesn’t occur after two obtained rota-
virus infections [27,28]. The acquired immune response is represented 
by T cells recognizing epitopes on the surface of the infected cell and B 
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cells producing antibodies against virus specific proteins, including 
neutralizing antibodies directed against the outer layer proteins VP7 and 
VP4 [29]. Non-neutralizing antibodies against the structural proteins 
VP2 and VP6, as well as against NSP2 and NSP4, have also been found 
in serum from convalescing individuals. The clinical importance of 
these antibodies and whether they are protective is not known [26].   
1.1.3 Rotavirus vaccine 
Two vaccines have been available since 2006, Rotarix (GlaxoSmithKline 
Biologicals, Rixensart, Belgium) and RotaTeq (Merck and Co, Inc, 
Pennsylvania, USA), and licenced in over 100 countries. Rotarix is a live 
attenuated vaccine based on a human G1P1A[8] rotavirus strain, and is 
given in two oral doses.  RotaTeq is also a live vaccine taken orally at 
three occasions, but contains five rotaviruses produced by reassortment. 
Four of these express different VP7 (serotypes G1, G2, G3, or G4) 
from a human rotavirus strain and the attachment protein VP4 of type 
P7[5] from bovine rotavirus. The fifth virus expresses VP7 of serotype 
G6 from a bovine rotavirus and VP4 of type P1A[8] from human rota-
virus. The two vaccines have been shown to have an equal protective 
effect. In 2009, World Health Organization (WHO) recommended all 
countries to include rotavirus vaccination in their national immunisation 
programs, especially those countries with high diarrhoea mortality rates 
in children [30,31]. In January 2017, 92 countries globally had 
introduced rotavirus vaccine, 85 in their national immunisation 
programs.  
 
In Latin America and Caribbean, several countries had an early 
introduction of rotavirus vaccination, already in 2006 and 2007, which 
had a dramatic impact on rotavirus infections. Several studies as well as 
meta-analyses have shown a vaccine efficacy of 71-85% against severe 
rotavirus diarrhoea and 73-90% against hospitalization due to rotavirus 
infection [32-35]. 
 
These vaccines also seem to be effective in African populations, but 
there were some concern that the protection might be inferior because 
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early case-control studies in different countries showed a variable 
vaccine efficacy, ranging between 18% and 77% against severe rotavirus 
diarrhoea in different countries [36,37]. Concern was also based on ob-
served mismatches between the subtype of the vaccine and the subtype 
of rotaviruses circulating in this region [38-40]. In studies performed in 
high and middle income countries Rotarix and RotaTeq seem to induce 
similar broad protection against homotypic strains that matched the G-
types and P-type included in the vaccines, and heterotypic strains that 
did not match any serotypes in the vaccines [41-43]. In total, 32 African 
countries have introduced rotavirus vaccination, of which 26 uses 
Rotarix and 6 uses RotaTeq. Rotavirus vaccination was introduced in 
the general immunization program in May 2012 in Rwanda (RotaTeq) 
and in February 2013 in Zanzibar (Rotarix). New published data, some 
years after vaccine introduction, from several African countries have 
documented a positive effect of rotavirus vaccination, but the methods 
to measure and report the efficacy are somewhat inconsistent, which 
makes data difficult to compare. A 23%-52% reduced hospitalization 
due to rotavirus infection has been observed among children less than 1 
year of age, whereas the effect on children aged 1-4 years varies from a 
modest reduction to even more cases in some regions [44-48]. A 
compilation of the reduction in hospital admission in different age 
groups and different countries is presented in Table 1.  
 
In high and middle income countries the vaccine effectiveness against 
rotavirus hospitalization is 81%-93% [35,49-56].  In Sweden, deaths due 
to rotavirus in children under 5 years of age are very rare, but the num-
ber of hospital admissions is estimated to be 2,100 and visits to an 
emergency room 3,700 every year. The ministry of health in Sweden 
estimates further that 14,000 children with rotavirus gastroenteritis visit 
primary care and that 30,000 children are treated at home each year be-
cause of rotavirus infection [57]. The cost caused by rotavirus infection 
was estimated one decade ago in several European countries, among 
them Sweden. The cost per episode of confirmed rotavirus gastro-
enteritis in Sweden was estimated to 2,101 euro [58]. Finland, where 
rotavirus vaccination was included in the national immunisation pro-
gram already in 2009, has reported a 91% reduction of rotavirus infec-
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tion in out-patients less than 5 years of age [59]. In Sweden, rotavirus 
vaccination has yet only been introduced in some regions, but is 
planned to soon be included in the national immunisation program. 
 
Table 1. Reduction in hospital admission due to rotavirus in African 
countries.  
 
Country Pre vaccine  Post vaccine  Age 
(years) 
Difference in 
hospitalization between 
pre- and post-vaccine	
Ref. 
Togo 2008-June 2014 July 2014-June 2015 <1	
1-4 
-23%	
-4% 
 
[48] 
Botswana 2009-2012 2013-2014 <1	
1-2	
2-5 
-43%	
-20%	
+14% 
 
[47] 
Ghana 2009-Mars 2012 April 2012- 2014 <1	
1-2	
2-5 
-24%	
-15%	
no reduction 
 
[45] 
Tanzania 
(Zanzibar) 
2010-2012 2013-2014 <1	
1	
2-4 
-52%	
-30%	
-25% 
 
[46] 
Malawi Jan 2012-June 2012 2013-2015 <1	
1-4 
-48%	
+38,5% 
 
[44] 
Rwanda 2011 2013-2014 < 5 -29% [60] 
1.1.4 Genotype circulation 
As mentioned, G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8] are con-
sidered to be the most common circulating genotypes worldwide. The 
predominance of certain genotypes fluctuates over time, and may vary 
at the same time in different areas. Rare genotypes, for instance G6P[6] 
and G8, often of bovine origin seem to be more common in Africa 
[39,61-64]. The fluctuation of genotypes in East African countries over 
a few years, prior to the introduction of rotavirus vaccination [65-69], is 
presented in Figure 3. After vaccine introduction, genotype fluctuation 
has continued, and a markedly increased incidence of G12P[8] has been 
observed in Australia, Europe and Latin America [21,70,71]. 
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Figure 3. Genotype distribution of rotavirus in some East African countries before 
vaccine introduction. 
 
1.2 ETEC and Shigella 
Despite improvements of water quality and sanitation, and the intro-
duction of rotavirus vaccination, the incidence of acute diarrhoea 
remains high among children less than five years of age in the 
developing world. ETEC and Shigella are the two most important 
bacterial pathogens for which there are no currently licensed vaccines.  
 
ETEC is usually acquired by ingestion of contaminated food or water 
and may cause watery diarrhoea. ETEC strains are characterized by the 
production of binding proteins called colonization factors (CF) and at 
least one of two enterotoxins: heat labile toxin (LT) and heat stabile 
toxin (ST). The gene coding for LT is called eltB and the gene coding 
for ST is called estA [72]. Approximately one-third of the ETEC strains 
isolated from diarrheic patients express only LT, one third only ST, and 
another third both toxin types [73]. ETEC strains infect the host epithe-
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lial cells in small intestine using CF antigens to adhere, and production 
of LT and ST may lead to over secretion of fluids and electrolytes, lead-
ing to diarrhoea [72]. CF and LT induce immunity. The immunity pro-
vides only short-term protection for LT, and because there are approx-
imately 30 genetically different CF, the immunity towards this antigen is 
often insufficient.  The ST is a short peptide that is poorly immuno-
genic [74].  
 
Shigella, like ETEC is transmitted by infected food or water, and since 
the infectious dose is low, person-person transmission is also possible. 
Shigella is genetically very similar to E. coli, and may be considered as an 
E. coli with certain phenotypic characteristics. Shigella is still classified as 
a separate genus and divided into four species; S. dysentariae, S. flexneri, S. 
sonnei and S. boydi [75,76]. The most important species in Africa is S. 
dysenteriae and S. flexneri, because they are more frequent and have a great 
clinical impact. They cause invasive infection of the colon, and may in-
duce watery diarrhoea as well as bloody diarrhoea, i.e. dysentery. S 
dysenteriae may produce Shigatoxin which can cause additional 
complications, including life-threatening kidney damage, besides severe 
diarrhoea [77]. 
 
Overall, the majority of studies indicate that ETEC producing ST alone 
or in combination with LT, are more strongly associated with diarrhoea 
than ETEC producing only LT. The frequency of ETEC producing ST 
among children in developing countries with diarrhoea is 4%-19% [9-
12,78] and globally ST strains are responsible for an estimated 5% of 
deaths due to diarrhoea [5]. LT is frequently detected among asympto-
matic controls [8,10,11,79], probably reflecting that acquired immunity 
prevents disease but not infection. ETEC producing ST infections are 
most important in the second year of life [11,78] and considered to be 
less frequent with higher age. However, in sub-Saharan Africa and 
South Asia, ETEC and Shigella infections in older children, adolescents 
and adults represent an underestimated problem that contributes to lost 
productivity and school absence, especially among children 5–14 years 
of age [80]. 
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Shigella is one of the most important causes of diarrhoeal disease among 
children in developing countries, causing an estimated 11% of deaths 
due to diarrhoea according to GBD [5]. The frequency of Shigella in 
children less than 5 years of age, living in developing countries, is 4%–
13%. Among children older than 2 years, an adjusted attributable 
fraction (AF), i.e. contribution of a risk factor or pathogen to a disease, 
of 35% has been shown. [8-10,12,78,81,82]. 
1.2.1 Vaccines 
Vaccination against ETEC and Shigella, especially by a combined vaccine 
against both pathogens, would be extremely valuable for saving lives 
and promoting the health of infants and children in the developing 
world [83,84]. There has been a range of vaccine candidates and 
research on potential vaccine components for ETEC is constantly on 
going, supported among others by WHO, but today there is no licensed 
vaccine available. Ducoral, vaccine against the Vibrio cholerae 
enterotoxin, is used to prevent ETEC associated travellers diarrhoea, 
probably protective by LT being similar in structure and function to 
cholera enterotoxin [85]. The main obstacles to designing a vaccine 
against ETEC are the great diversity of strains, their virulence repertoire 
and the poor immunogenicity of ST [86,87]. Humans being the only 
reservoir for Shigella complicate vaccine development since there is no 
animal models that successfully replicate Shigellosis. The main candi-
dates for Shigella vaccine are whole-cell and conjugated vaccines [86].  
 
Oral vaccination. www.alamy.com F4785Y  	
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1.3 Other enteric pathogens of clinical 
importance 
The importance of pathogens infecting humans varies in different 
populations. The most important enteric pathogens that, besides rota-
virus, ETEC and Shigella, may cause acute gastroenteritis in children are 
presented below.  
1.3.1 Adenovirus  
Adenovirus is non-enveloped DNA virus, divided in 7 species (A-G) 
and classified in more than 50 subtypes or serotypes. Adenoviruses are 
frequently detected in children, among whom acute respiratory infection 
is the most common clinical presentation, but subtypes 40-41 and 52 
belonging to species F respectively G mainly cause diarrhoea [88,89]. 
Other subtypes are commonly detected in faecal samples but whether 
they cause diarrhoea is insufficiently known.  
 
In our previous studies, related to this thesis, adenovirus of any type 
was detected in 40% of patients and 42% of the healthy controls. 
Adenovirus of types 40/41 was detected in 7.0% of patients and 6.8% 
of controls and there was no association with diarrhoea [8,9]. A study 
performed in Tanzania show lower frequencies of adenovirus infection, 
3.5% in patients and 2.4% in healthy controls, possibly explained by the 
lower sensitivity in detection method (enzyme-linked immunosorbent 
assay vs. polymerase chain reaction (PCR)). They reported that adeno-
virus was significantly associated with diarrhoea in children less than 
one year [90]. Similarly, a reanalysis of data from GEMS showed that 
adenovirus 40/41 was one of the most important causes of diarrhoea, 
estimated to cause 11% of cases in children less than one year [12]. 
1.3.2 Astrovirus 
Astrovirus is a non-enveloped virus with a positive sense, single-
stranded RNA, belonging to the Astroviridae family. Astrovirus has 
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been identified as a common viral aetiology of acute gastroenteritis in 
children, but causes outbreaks also in adults and elderly [91,92]. In 
African studies astrovirus has been detected in 4.5%-6% of children 
with diarrhoea, significantly more often than in non- diarrhoea controls, 
especially in children aged 1-5 years [9,93-95].  
1.3.3 Norovirus 
Noroviruses are non-enveloped, single-stranded RNA viruses belonging 
to Caliciviridae family. Noroviruses are classified in five genogroups 
(GI–GV), of which GI, GII, and GIV infect humans [96]. GII, and in 
particular genotype GII.4, has been most strongly associated with 
diarrhoea, causing >80% of gastroenteritis outbreaks [97]. Noroviruses 
are highly contagious pathogens and they affect individuals of all age 
groups in high- and low-income countries. They are transmitted by 
faecal contaminated food and water, by person-to-person contact, or 
through aerosol of the virus [98-100]. Norovirus often induces cascade 
vomiting and intense diarrhoea after an incubation period of 24-48 h, 
with symptoms normally lasting a few days [101]. It is not well known 
whether human norovirus infections induce any lasting protective 
immunity or to what extent immunity protects against exposure to 
different strains [102]. This is important because noroviruses are highly 
genetically diverse, making the development of an efficient norovirus 
vaccine a challenge.  
 
Both longitudinal [103] and case-control studies [104] have shown that 
norovirus infections in children in low-income countries often are 
asymptomatic, but  also that they are causing a significant part of 
diarrhoea in children under five years of age [9,13,78]. 
1.3.4 Sapovirus  
Sapovirus, like noroviruses, belongs to the Caliciviridae family and are 
divided in to five genotypes, GI-GV, of which all but GIII infect 
humans. Sapovirus infect both human of all ages and animals, causes 
both sporadic cases and outbreaks of acute gastroenteritis worldwide. 
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The clinical importance of sapovirus in African children with diarrhoea 
is not well documented, but sub-Saharan studies show a detection fre-
quencies between 8% and 18% in children < 5 years with diarrhoea 
[10,81,94,95,105], and 4%-11% in non-diarrhoea controls [9,10,95]. 
1.3.5 Campylobacter  
Campylobacter are gram-negative bacteria belonging to the Campylo-
bacteriaceae family. There are several species that infect humans, with 
C. jejuni and C. coli, being the clinically most important. Campylobacter is 
the most common cause of bacterial diarrhoea in industrialized 
countries. It is an important aetiology also in and low-income settings 
[106], and is estimated to cause 6.2% of deaths due to diarrhoea in sub-
Saharan African children less than 5 years of age [5]. In industrialized 
countries, both children and adults are affected by Campylobacter through 
traveling or outbreaks related to consumption of poultry products or 
water, often present with abdominal pain, fever and bloody diarrhoea 
reflecting invasive colitis that may last for 7 days or more. Campylobacter 
is endemic in many low-income countries causing diarrhoea especially in 
children under 1 year of age, with asymptomatic infection increasing 
with age [107], suggesting that repeated exposure in early life leads to 
the development of protective immunity [108]. 
1.3.6 Enteropathogenic Escherichia coli  
Enteropathogenic Escherichia coli (EPEC) do not produce toxins or have 
invasive properties, but may cause diarrhoea by other mechanisms. The 
only known reservoir for EPEC is humans. EPEC are usually classified 
by molecular techniques that include identification of genes coding for 
intimin (eae gene) and bundle forming pilus (bfpA gene). Typical EPEC 
carry both the eae and bfpA genes, whereas atypical EPEC code only for 
eae [109]. Whether the atypical EPEC cause any disease in humans is 
debated. Diarrhoea due to EPEC decreases with age and studies 
conducted worldwide have shown that typical EPEC are mainly 
associated with diarrhoea in children <1 year of age, especially in low-
income countries [11,110-112] . Infections in adults or older children 
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are rarely reported. This apparent resistance in adults has been 
attributed to the loss of specific receptors with age or development of 
immunity [113]. 
1.3.7 Salmonellae 
Salmonellae are gram-negative bacteria of the Enterobacteriaceae family, 
classified in two species, S. enterica and S.bongori. S.enterica, a common 
cause of infectious disease in humans and animals throughout the 
world, is further divided in subspecies and nearly 1,500 serological 
variants (serovars). Human Salmonellae infections are classically divided 
into diseases caused by typhoidal (infection by servoar Typhi or Para-
typhi) or non-typhoidal salmonellae [114]. The former category causes the 
systemic disease typhoid, while non-typhoidal salmonella is comprised 
of the majority of other serovars that predominantly cause 
uncomplicated gastroenteritis in high-income countries [115], but 
frequently causes  invasive bacterial disease in sub-Saharan Africa 
[116,117]. Its epidemiology among children in low-income countries is 
insufficiently studied, but it appears to be an important cause of 
gastroenteritis, detected in about 5% of children and less often in 
healthy controls [10,81]. The rate of antibiotic resistance, both against 
typhoidal and non-typhoidal strains, is alarming [118] and WHO 
recommends use of the two available licenced vaccines against typhoid 
fever [119]. 
1.3.8 Cryptosporidium  
Cryptosporidium is a protozoa that forms oocysts, which after ingestion 
releases sporozoites that infect enterocytes. In acute infections, 
diarrhoea is often accompanied by fever and vomiting, sometimes caus-
ing dehydration that requires hospitalisation. There are several species, 
which infect different hosts. The two main species are C. hominis, which 
infects only humans, and C. parvum, which infects humans as well as 
animals. Cryptosporidium infections appear with seasonal variation, 
occurring more frequently at higher temperature and more rainfall. 
Animal exposure, particularly cats and cattle, is also associated with 
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increased risk of infection [120]. Cryptosporidium has been detected in 
between 4% and 30% of children in low-income countries, and is 
strongly associated with diarrhoea. It is in particular a major cause of 
acute gastroenteritis among children below 5 years of age [10,11,78]. 
Prolonged infections also appear to be common, and have been 
associated with malnutrition, in particular with stunting [121,122].  
1.4 Co-infections  
In the studies of diarrhoea aetiology, sensitive molecular methods 
targeting virus, bacteria and parasites, have revealed that several 
pathogens often are present in the same faecal sample [9,11,12,123,124], 
in particular in low-income countries. The observed rates of 
polymicrobial infections in patients with diarrhoea vary between 20-
76%, depending on geographic area, the number of targeted pathogens 
and detection method. Infections with several pathogens are more rare 
in controls without diarrhoea, as shown in Table 2.  
 
The importance of co-infections, and whether more than one agent 
contributes to the symptoms in patients in whom multiple pathogens 
are detected, is not well known. Studies on co-infections are rare, their 
results inconsistent, and the interpretations are not always justified. One 
study from Ecuador reported that co-infections with rotavirus and 
Giardia as well as with rotavirus and E.coli/Shigella had synergistic effect 
on symptoms [125]. Another study, conducted in China, reported that 
co-infections with rotavirus and norovirus GII increased the severity of 
diarrhoea [126].  
 
Pathogens that independently can cause diarrhoea should of statistical 
reasons show negative associations among patients (unless acting syner-
gistically on symptoms) but not among healthy controls. Negative 
associations were recently reported for Vibro cholerae and any of 
rotavirus, adenovirus, Cryptosporidium, Shigella and ETEC, but possible 
interpretations of this finding were not discussed [127].  
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Table 2. Proportion of samples with more than one pathogen detected. 
 
Patients	 Controls	 Country	 Methodology	 Pathogen panel	 Ref	
 
45%	  31%	  GEMSa	  Culture, ELISA, PCR	  Broadc	  [11]	
41%	 29%	 MAL-EDb	 Culture, ELISA, PCR	 Broadc	 [78]	
21%	 4%	 Ecuador	 Culture, PCR, 
immunochromatograpy	 Limited (6 pathogens)	 [125]	
20%	 5%	 China	 Culture, PCR	 Limited (7 pathogens)	 [126]	
76%	 60%	 Zanzibar	 Real-time PCR	 Broadc	 [10]	
63%	 57%	 Rwanda	 Real-time PCR	 Broadc	 [8]	
35%	 8%	 Jordan	 Culture, PCR	 Broadc  (except viruses, 	
only rotavirus)	 [128]	
27%	 15%	 Ghana	 Culture, Microscopy, PCR	 Broadc	 [129]	
a Kenya, Mali, Mozambique, The Gambia, Bangladesh, India, and Pakistan. 
b Bangladesh, India, Nepal, Pakistan, South Africa, Tanzania, Brazil and Peru. 
c Including a wide range of pathogens; bacteria, viruses and protozoa that causes 
diarrhoea. 
 
 
To further evaluate the importance of co-infections, especially rare 
combinations, further studies, fulfilling the following requirements, are 
needed:  
 
• Large number of both patients and controls are needed to 
obtain sufficient number of each pathogen combination to 
allow accurate statistics.  
 
•  Documentation of relevant symptoms. 
 
• The analytical methods should target a wide range of pathogens 
– virus, bacteria and protozoa – and should have high and 
equal sensitivities.  
 
• The studies should be performed in different geographic areas 
and during different time periods since the importance of co-
infections may be influenced by season, climate and socio-
economic factors.  
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1.4.1 Concepts to interpret and present polymicrobial 
infections 
Association tells whether two variables are related to each other, posi-
tively or negatively. Regarding pathogens, positive and negative associa-
tion describe if they occur together more or less often than expected 
from the frequency with which they are detected alone. In addition, the 
pathogen concentration or quantitative parameters can correlate.  
 
Thus, enteric pathogens that can cause diarrhoea should show negative 
associations among patients (unless acting synergistically on symptoms), 
but not among healthy controls. 
 
A positive association may be observed if pathogens act synergistically 
on symptoms, i.e. if they cause more severe symptoms together than 
would be expected from the effect of each agent alone. Such synergy 
may counteract the anticipated negative association within the patient 
group mentioned above. Presence of a synergistic effect on diarrhoea 
can be evaluated by calculating the odds ratio (OR) of a pathogen or a 
pathogen combination to occur, in patients compared to healthy 
controls. Synergistic interaction is presented if the ratio of  
ORco-infection/(ORsingle infection 1 x ORsingle infection 2) exceeds 1.  
 
Whether a certain co-infection aggravates symptoms in persons who are 
sick can also be studied by comparing the severity of symptoms, for 
example the degree of dehydration, in patients with co-infection and 
those with pathogen alone. 
 
Positive associations between pathogens can also be found in both 
patients and controls. Such associations can reflect that pathogens de-
pend on the same environmental or host factors for their transmission 
or ability to infect. Positive associations can also be observed if the 
target genes used for detection are present in the same virus particle or 
bacteria. 
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1.5 Asymptomatic infections 
Beyond higher frequency of co-infection among patients with diarrhoea, 
the use of more sensitive molecular methods have also revealed that 
enteric infection is very common among asymptomatic controls. The 
most likely explanation to acquired immunity after a previous infection 
abrogates symptoms but does not prevent infection. In addition, there 
are other possible explanations for finding pathogens in asymptomatic 
controls. In some cases an infection might seem to be asymptomatic, if 
sampling was performed during a shedding period after recovery from 
diarrhoea [130-132]. Asymptomatic infections might also be the result 
of a low infectious dose in patients that do not have acquired immunity, 
or be caused by bovine pathogens incapable of causing human disease. 
The presence of maternal secretory immunoglobulin A antibodies from 
breast milk, or protective host factors such as variants of blood group 
antigen (demonstrated for norovirus and cholera) [133], can also 
prevent symptomatic infection.  
 
1.6 Important risk factors for diarrhoea  
1.6.1 Unsafe Water, Unimproved Sanitation and Hygiene 
The WHO/UNICEF Joint Monitoring Program working with the 
access to safe drinking water and basic sanitation reported in 2015 that 
91 per cent of the global population uses an improved drinking water 
source. In sub-Saharan Africa 68% of the population have access to 
improved drinking water, but still 100 million people use surface water. 
Improved sanitation facilities are available for 68% of the global popu-
lation but reach only 30% of the sub-Saharan population [134]. 
 
Unimproved drinking water is defined as unprotected springs and dug 
wells, surface water and water stored in a tank.  
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Improved drinking water is protected springs, public taps/standpipes or 
running water in dwelling.   
 
Improved sanitation facilities is defined as flush toilets and pit latrines 
using the flush/pour flush method that are connected to either a sewer 
or a septic system, ventilated improved pit latrines, and pit latrines with 
slab and composting toilet. Sanitation facilities that are shared by two or 
more households, even if improved, are classified as unimproved 
because shared sanitation facilities tend to be less hygienic and less 
accessible than private sanitation facilities used by a single household. 
Sanitation also includes distribution of disposal of garbage on a hygienic 
basis [135].  
 
The frequency of diarrhoea is related to water quality and facilities, and 
there is a potential to reduce diarrhoeal disease through improvements 
of both water supply and sanitation in low- and middle-income settings. 
It has been shown that pathogens, like E. coli, detected in the drinking 
water are associated with an increased prevalence of child diarrhoea 
[136]. The most effective measure to improve water for individual 
households is the use of filter, boil or chlorinate at the point of 
consumption in combination with safe water storage. At the community 
level, introduction of high-quality piped water of good microbial quality, 
supplied continuously (minimize the use of unsafe water) to the 
household is the most effective improvement [137-139].  
 
The impact of improved sanitation on diarrhoea has not been studied to 
the same extent as the impact of water quality, but reviews based on 
available data indicate that a 30% reduction of diarrhoea could be 
achieved [139,140]. Miserable conditions in the slum, sanitation facility 
shared by six or more households, presence of faeces on the floor 
around sanitation facility as well as uncollected garbage indoors were 
significantly associated with acute diarrhoea in a study performed in 
Ethiopia [141]. Introduction of sewage sanitation in urban areas in low-
income settings would be expected to have a positive impact on health 
with decreased frequency of diarrhoea even if improved latrines would 
alleviate the sanitation problem [137]. Simple improvements like intro-
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duction of coverage for latrines were shown to significantly reduce the 
prevalence of diarrhoea in children under 4 years of age living in Congo 
[142].  
1.6.2 Malnutrition 
Malnutrition is divided in wasting (low weight-for-height), stunting (low 
height-for-age), underweight (low weight-for-age) and deficiencies in 
vitamins and minerals. To measure nutrition status, Z scores (standard 
deviation scores) for anthropometric data can be calculated, and 
typically reported using a cut-off value, with <–2 defining moderate to 
severe malnutrition, <–3 defining severe malnutrition, and >+2 
defining overweight [143,144]. Malnutrition is both consequence of and 
a risk factor for diarrhoeal disease. For example, Cryptosporidium parvum 
impairs nutrient absorption and has been shown to have a lasting 
adverse effect on height growth, especially when acquired during 
infancy [121,122]. Both symptomatic and asymptomatic Campylo-
bacter infections in Peruvian children were associated with poorer weight 
gain while symptomatic infections additionally were marginally associ-
ated with poorer height growth [145]. In a study performed in 
Bangladesh, infection with Cryptosporidium, LT producing ETEC, Shigella, 
norovirus GII, and Giardia were more commonly detected in mal-
nourished cases than controls [146]. Children who die from diarrhoea 
often suffer from underlying malnutrition, which makes them more 
vulnerable to diarrhoea and dehydration. Each diarrhoeal episode, in 
turn, makes their malnutrition worse [147].  A decrease in the gut 
permeability and the amount of inflammatory cells in intestine, as well 
as increase of gastric acid production and vaccination titre response are 
immune parameters among others that have been shown to be affected 
by malnutrition, but the mechanisms for immune dysfunction in 
malnourished children is still poorly understood [148]. 
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1.7 Persistence and clearance of enteric 
pathogens 
Persistent diarrhoea in infants and young children living in low-income 
countries is associated with a greater risk of subsequent growth faltering 
and high mortality [149]. It is however not well known to what extent 
persistent diarrhoea is due to persistent infection. In order to elucidate 
this question longitudinal studies that both document symptoms and 
analyse pathogens are required. However, such studies are rare and 
usually focus on one or a few pathogens. Longitudinal studies are also 
required to clarify to what extent persistent infections explain the high 
prevalence of enteric pathogens in children in poor living conditions. 
An alternative explanation could be a heavy environmental exposure. 
 
Three longitudinal studies with repeated sampling of children in Brazil 
showed that the mean number of diarrhoea episodes was on average 5 
per child and year [150-152]. Persistent diarrhoea (last ≥ 14 days) was 
observed in 5-8% in these studies but whether enteric pathogens 
persisted in children without diarrhoea was not well studied. A study 
from Bangladesh in children less than one year showed a mean 
incidence rate of infectious diarrhoeal events of 4.7 per year with a 
mean duration of these episodes of 5.5 days [152]. The association 
between persistent diarrhoea and specific pathogens is not well known, 
but long-lasting protozoa infections are considered to be of particular 
importance [153,154].  
 
A longitudinal study from Cameroon, including monthly sampling 
during one year reported that 6% of norovirus infections lasted longer 
than 1 month [155]. In Guinea-Bissau, longitudinal sampling with focus 
on ETEC showed that the majority (81%) of ETEC infections were 
cleared within 2 weeks [156]. 
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2. Aims  
The overall aim of this thesis was to investigate enteric infections in 
children in Rwanda and Zanzibar below five years of age, with focus on 
co-infections, short-term course and impact of rotavirus vaccination.  
 
The specific aims were: 
 
Paper I 
To characterize associations between different enteric pathogens or 
virulence genes in children with or without diarrhoea. 
 
Paper II 
To determine to what extent enteric infections among these children 
were cleared or acquired two weeks after acute gastroenteritis. 
 
Paper III 
To develop a new rotavirus genotyping method and apply it to study 
rotavirus genotypes in Sweden. 
 
Paper IV 
To investigate how rotavirus vaccination in Rwanda has influenced the 
number of rotavirus infections, their genotype distribution and clinical 
presentation. 
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3. Materials and Methods  
3.1 Patients 
The number of included patients and healthy controls from each 
location, sampling year and in which paper they are a part of is 
presented in Figure 4. 
 
 
Figure 4. Number of included samples from Rwanda, Zanzibar and Sweden. 
3.1.1 Rwanda  
Children seeking care in 5 health centres, 3 district hospitals and 2 
university hospitals were included during both the main raining season 
(from March to May) and the main dry season (July to August) in 
January 2009 – April 2012.  After vaccine introduction in May 2012, 
additional patients from 6 district hospitals and 2 university hospitals 
were included between Junes 2014 to December 2015. The localisation 
of hospitals and health care centres are presented in Figure 5. The inclu-
sion criteria was age ≤5.0 years and diarrhoea with a duration of <96 
hours (with or without vomiting or fever). Diarrhoea was defined as 
Rwanda 
Zanzibar 
Sweden 775 patients 
165 patients 
165 healthy controls 
829 patients 
159 healthy controls 
818 patients 
127 Follow-up 
2009-2012 
2009-2012 
2014-2015 
2011 
2011 
2011 
2010-2014 
I, IV 
I 
I, II 
II 
I 
III 
IV 
Paper Sampling year Number Location 
	
 
26   MARIA ANDERSSON 	
 
passage of 3 or more loose or watery stools per day, but in breast-
feeding infants, diarrhoea was considered when they had more than 6 
stools per day.  
 
The healthy controls included were children below 5.0 years of age, 
living in the same geographic area as the patients, without any episode 
of diarrhoea in 14 days prior to the sampling date. Nurses and 
community health workers at nursing schools and immunization centres 
recruited them during the same time period as patients in 2010–2012.  
 
 
 
 
Figure 5. University Hospitals (UH), District Hospitals (DH) and Health care centres (HC) 
included in the study conducted in Rwanda. Health cares facilities written; in red were 
included in 2009–2012, in blue 2014–2015 and in black both periods.  
CHUK (UH) 
Kabagabaga DH 
Muhima DH 
Bethsaida HC 
Nyarugenge HC 
Gitega HC 
 
CHB (UH) 
Kabutare DH 
CuspButare HC 
Rango HC 
 
Ruhengeri DH 
Kabgayi DH 
Rwamagana DH 
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3.1.2 Zanzibar 
Children (n=165) with diarrhoea who participated in a larger study of 
fever aetiologies, carried out during April-July 2011, were included in 
this work. Sampling was performed during the end of the rainy season 
and beginning of the dry season. The patients were aged 2-59 months 
and attended Kivunge Primary Health Care Centre in rural Zanzibar 
(North A district) with fever (measured axillary temperature of ≥37.5˚C 
or a history of fever during the preceding 24 hours according to the 
accompanying guardian) and diarrhoea (history of loose stools during 
the preceding 24 hours). A part of them (n=127) revisited the health 
care centre 14 days after initial sampling, when a follow-up sample was 
collected.  
 
This study also included healthy controls that were children aged 2-59 
months, matched for living area and sampling time period, and having 
no history of diarrhoea, cough, running nose or fever in the preceding 
10 days.  
3.1.3 Sweden 
During January 2010 to December 2014, 18,996 clinical samples, the 
majority from patients with acute gastroenteritis, were received at the 
molecular virology unit of the department of Clinical Microbiology, 
Sahlgrenska University Hospital in Gothenburg. Rotavirus was identi-
fied in 4.9% and these samples were analysed with a real-time PCR 
genotyping method that we developed (Chapter 3.4).  
3.1.4 Classification of dehydration 
A thirsty, restless and irritable child with sunken eyes and a skin that 
returns slowly to normal structure after pinch is classified as having a 
moderate dehydration, while a child who is lethargic or unconscious, 
not able to drink, with very sunken eyes and a skin that normalizes very 
slowly after pinch is severely dehydrated, according to WHO guidelines. 
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3.1.5 Anthropometric data  
For assessment of nutritional status, weight, height, and upper arm mid 
circumference were recorded in participating patients in Zanzibar. From 
these data we calculated z scores of height for age, weight for height, 
and mid upper arm circumference for age, using the World Health 
Organization Anthro for personal computers, version 3.2.2, 2011. 
3.2 Sample material and nucleic acid extraction  
Stool samples from Rwanda and Sweden were collected with a rectal 
swab (Copan Regular Flocked Swab 502CS01, Copan Italia Spa, Brescia, 
Italy) in a tube with 1 mL of sterile saline, or as faeces. The samples 
from Zanzibar were all collected as rectal swabs. The samples from 
Rwanda and Zanzibar were stored in a local laboratory at -80 ºC until 
transport to Sweden.        
 
Approximately 250 µL of faeces were dissolved in 4.5 mL of saline and 
centrifuged 5 min at 750xg. Then, 250 µL of dissolved faeces or 250 µL 
of rectal swab fluid were mixed with 2 mL of lysis buffer, and this 
volume was used for extraction of total nucleic acid in an EasyMag 
instrument (Biomerieux, Marcy l’Étoile, France). The nucleic acids were 
eluted in 110 µL. These procedures correspond to an approximate 
dilution of faeces to 1:10 and the dilution of rectal swab samples 
depends on the specimen volume contained in the swab, but estimated 
to be between 1:10 and 1:100.  
3.3 Pathogen panel 
All samples from patients and healthy controls that were collected in 
Rwanda 2009-2012 were analysed by an in house multiplex real-time 
PCR panel as previously described [10,157]. The enteric panel targeted 
adenovirus, astrovirus, norovirus GI or GII, rotavirus, sapovirus, 
Campylobacter jejuni, Cryptosporidium parvum/hominis, ETEC-eltB, ETEC-
estA, EPEC-eae, EPEC-bfpA, Salmonellae, Shigella, Vibrio cholera and 
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Yersinia enterocolitica. In the analyses of the second set of samples from 
Rwanda (2014-2015) adenovirus, Vibrio cholera and Yersinia enterocolitica 
were excluded. In the analyses of samples from Zanzibar, EPEC-eae and 
EPEC-bfpA were excluded from the panel. Due to the low numbers 
detected, norovirus GI, Vibrio cholera and Yersinia enterocolitica, these 
agents were excluded from the analyses of co-infections and cause of 
infection in papers I and II, and likewise Salmonellae was excluded from 
the analysis of the cause of infection in paper II. 
3.4 Method development of multiplex real-time 
PCR for genotyping of rotavirus 
We developed a new real-time PCR-based method for genotyping of 
rotavirus, which was applied in paper III and IV. The development of 
the method is described below. 
3.4.1 Primers and probes 
Nucleotide sequences representing each VP7 (G1, G2, G3, G4, G9 and 
G12) and VP4 type (P[4], P[6] and P[8]) were downloaded and aligned. 
Primers and probes were designed to discriminate between genotypes. 
They were located to segments that were conserved within the targeted 
genotype, but differed to other genotypes either at the 3’ ends of either 
primer or at one or several positions in the probe. These matches and 
mismatches were presented as heat maps in paper III. In Figure 6, heat 
maps show the reactivity for the systems against the sequences from 
strains included in Rotarix and RotaTeq vaccines respectively.  
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A	 VP 7	
Number of mismatches	
 
 Rotarix	 RotaTeq	
 G1	 G1	 G2	 G3	 G4	 G6	
G1 Forward Primer	 1	 1	 3	 6	 5	 4	
G1 Reverse Primer	 0	 2	 8	 5	 2	 6	
G1 Probe	 0	 0	 4	 5	 3	 6	
G2 Forward Primer	 10	 10	 1	 14	 15	 13	
G2 Reverse Primer	 3	 3	 1	 5	 5	 4	
G2 Probe	 4	 5	 1	 7	 7	 1	
G3 Forward Primer	 3	 3	 3	 1	 3	 5	
G3 Reverse Primer	 11	 12	 4	 3	 9	 4	
G3 Probe	 9	 11	 10	 4	 9	 6	
G4 Forward Primer	 5	 4	 4	 5	 1	 7	
G4 Reverse Primer	 7	 7	 6	 5	 3	 8	
G4 Probe	 3	 5	 4	 5	 0	 3	
G9 Forward Primer	 7	 9	 10	 7	 8	 9	
G9 Reverse Primer	 7	 7	 9	 5	 5	 7	
G9 Probe	 3	 4	 6	 1	 6	 7	
G12 Forward Primer	 9	 8	 6	 9	 10	 12	
G12 Reverse Primer	 8	 8	 5	 3	 9	 5	
G12 Probe	 8	 9	 9	 5	 8	 7	
 
B	 VP4	
Number of mismatches	
 
 Rotarix	 RotaTeq	
 P[8]	 P[8]	 P[5]	
P4 Forward Primer	 3	 3	 8	
P4 Reverse Primer	 3	 2	 15	
P4 Probe	 2	 1	 9	
P6 Forward Primer	 6	 4	 6	
P6 Reverse Primer	 6	 5	 7	
P6 Probe	 4	 4	 5	
P8 Forward Primer	 3	 4	 6	
P8 Reverse Primer	 3	 4	 16	
P8 Probe	 1	 2	 7	
 
 
 
 
Figure 6. Heat map showing the degree of fit 
between primers and probes for G types (A) or 
P types (B) and Genbank sequences 
representing the monovalent Rotarix and 
pentavalent RotaTeq vaccines. Green colour 
indicates very good fit (0-1 mismatch), yellow 
indicates 2-4 mismatches in primers and 1-2 
mismatches in probes, and red indicates 
presence of either a mismatch at the 3’ position 
of the primer or more than 4 mismatching 
positions in primer or probe. The matching was 
based on comparison with sequences with 
accession numbers HG917354 (G1) and 
HG917355 (P[8]) for Rotarix, and GU565057 
(G1), GU565068 (G2), GU565079 (G3), 
GU565090 (G4), GU565046 (G6), GU565044 
(P[8]), and GU565055 /GU565066 /GU565077 
/GU565088 (P[5]) for RotaTeq. Based on the 
matching one can predict that genotyping of a 
sample containing a Rotarix strain would be 
positive by the G1 PCR and probably also by 
the P[8] PCR (likely with a higher Ct value 
than for G1), and that a RotaTeq strain would 
be positive by the G1, G2, G4 and P[4] PCR, 
but negative by the P[8] PCR. 
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3.4.2 Multiplexing 
The evaluation of the real-time method for genotyping of rotavirus 
comprised the following steps: 
 
1. Firstly the performance of each real-time PCR was evaluated by 
analysis of serial dilution in five steps of a pUC57 plasmid containing 
the target regions for all real-time PCR systems (GenScript, Piscat-
away, NJ). This either confirmed sufficient amplification efficiencies 
or indicated that adjustments needed to be carried out.  
 
2. Optimization of primer concentration, annealing temperature and 
adjustment of the instrument temperature ramp rate.  
 
3. When all systems had a sufficient efficiency with a standard curve 
slope as close to -3.32 (efficiency 100%) as possible (Figure 7), every 
duplex combination was tested. This step showed the duplex combi-
nations that performed well.  
 
4. Triplex combinations were tested and accepted if the Ct value did not 
increase by more than 1 cycle as compared with each component 
PCR (Figure 7) and if analyses of serial dilutions indicated that the 
amplification efficiencies were good.  
 
5. In the last step of evaluation, patient samples with rotavirus detected 
in the clinical diagnostics (using a real-time PCR targeting NSP3 
gene) and 4 different Equalis panels from 2011–2014 including rota-
virus samples with known genotype were analysed by both single and 
multiplex real-time PCR.  
 
6. At least three samples of each genotype were confirmed by Sanger 
sequencing [158].  
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The genotyping method with three triplex reactions, presented in paper 
III, was then applied on rotavirus positive samples detected in Clinical 
Microbiology, Sahlgrenska University Hospital, Gothenburg, during 
2010–2014.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A C 
B Slope: 3,327 
R: 0,998 
Single (red and yellow curve) 
Multiplex 
Figure 7. Amplification plot in log scale for 
serial dilution of plasmid in P[4] single 
reaction real-time PCR, is illustrated in A and 
corresponding standard curve in B. Illustration 
C present an ideal P[4] real-time PCR in two 
different dilution of plasmid as single reaction 
and with no lost in efficiency in different 
multiplex reactions.  
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3.5 Statistical analyses 
Statistical analyses were performed using JMP® Statistical Software. 
3.5.1 Fisher’s exact test 
Fisher’s exact test is used to test if two categorical variables are associ-
ated. Often it is used to compare the proportions of a feature between 
two groups. This test was used in paper I to find potential pathogenic 
importance of co-infection. Presence of vomiting or dehydration in co-
infections and mono-infections were compared, for each pair of patho-
gens. In paper II Fisher’s exact test was used for comparison of detection 
frequencies between baseline and follow-up sample and to find possible 
association between z scores < –2 for height or weight and clearance, 
persistence or new infections. Furthermore, the test was used to analyse 
for each antibiotic-bacterial combination if prescription of antibiotics at 
baseline was associated with clearance of bacterial pathogens. Fisher’s 
exact test was further used in paper IV to compare groups as regards 
categorical data such as pathogen frequencies, rotavirus genotype, 
sampling time point, dehydration and age group. 
3.5.2 Mann-Whitney U test (rank sum test) 
Mann-Whitney U test is a non-parametric test that is used to compare 
two sample medians, assuming that the shape of the two distributions is 
the same.  In paper I, severity of certain symptoms; body temperature, 
frequency of diarrhoea or degree of dehydration, were compared be-
tween co-infection and mono-infection with Mann-Whitney U test.  
This test was also used in paper II when grouped Ct-values for each 
pathogen were compared between baseline sample and follow-up 
sample. Mann-Whitney U test was used in paper IV to compare groups 
as regards numerical data such as Ct values and age. 
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3.5.3 McNemar test  
The McNemar test is used with paired nominal data to test if there is a 
systematic difference between the two conditions. This test was applied 
in paper II to analyse if presence of a pathogen changed between base-
line and follow-up, i.e. the combined effect of cleared and new infec-
tions. 
3.5.4 Paired t test  
The paired sample t-test is used for paired numeric data, assuming the 
differences are normally distributed, to data to test if their mean differs 
from zero and this was applied in paper II to compare Ct values between 
baseline and follow-up in cases with persistent infection. 
3.5.5 Logistic regression  
Logistic regression is used to model the relationship between a binary 
response and one or more predictor variables. In paper I, associations 
between co-infection and symptoms, which might indicate synergistic 
interactions, were evaluated by logistic regression analysis for all pair-
wise pathogen combinations with presence of symptoms (i.e. patient vs. 
control) as dependent variable and detection (yes or no) of the two 
pathogens as independent variables, and with an interaction term of the 
two. Synergy was considered to be present if the odds ratio (OR) for co-
infection was greater than the product of the OR for each of the two 
compared pathogens.  
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4. Results and Discussion 
4.1 Paper I 
In paper I, associations between co-infecting pathogens were studied in 
samples from 994 children with diarrhoea and 324 healthy controls 
without diarrhoea, which originated from studies in Rwanda and 
Zanzibar. Among the patients, 65% had more than one pathogen 
detected, as compared with 58% in healthy controls. Table 3 summa-
rises the positive and negative associations that were statistically 
significant.  
4.1.1 Positive associations only in patients and association 
with symptoms 
Positive associations that were found in patients only might indicate 
synergistic impact on symptoms. As shown in Table 3, such associations 
were observed for several pathogen combinations. Three of them had p 
values ≤ 0.001 and OR>2: Campylobacter + ETEC-eltB, Campylobacter + 
Cryptosporidium and Shigella + EPEC-eae. 
 
To evaluate potential synergy further, logistic regression comparing 
detection rates in patients and controls was performed. This analysis 
showed that some co-infections were more frequent in patients than in 
controls also when their frequencies alone were taken into account. 
These co-infections were Shigella and EPEC-eae (OR = 4.85, (95% CI: 
2.51, 12.50), p = 0.01), and norovirus GII and EPEC-eae (OR = 5.57, 
(95% CI: 3.98, 5.86), p = 0.006).  
 
Shigella and EPEC-eae was the only co-infection of pathogens that aggra-
vated symptoms as compared with infection with each pathogen alone. 
This combination was significantly) associated with an increased 
frequency of diarrhoea (p<0.001).  
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Table 3. Associations between enteric pathogens. 
 
 No. 
co-infections 
OR 
 
P-valuea 
 
Positive association in patients     
Campylobacter + ETEC-eltB 56 2.03 0.0005 
Campylobacter + ETEC-estA 32 1.67 0.026 
Campylobacter + Cryptosporidium 37 2.11 0.001 
Astrovirus + ETEC-eltB 18 2.24 0.026 
Norovirus GII + EPEC-eae 28 1.78 0.027 
Salmonellae + ETEC-eltB 31 1.84 0.021 
Shigella + EPEC-eae 59 2.14 0.0001 
Shigella + EPEC-bfpA 34 1.86 0.0081 
Shigella+ Sapovirus 16 2.01 0.041 
    
Positive association in patients and healthy controls    
ETEC-estA+ ETEC-eltB 
Patients 
Healthy controls 
 
112 
41 
 
3.85 
6.02 
 
<0.0001 
<0.0001 
ETEC-estA+ Sapovirus 
Patients 
Healthy controls 
 
21 
10 
 
3.67 
3.81 
 
<0.0001 
0.0035 
EPEC-eae + EPEC-bfpA 
Patients 
Healthy controls 
 
75 
9 
 
6.09 
6.39 
 
<0.0001 
0.0024 
    
Negative associations in patients    
Rotavirus + Norovirus GII 9 0.19 <0.0001 
Rotavirus + Campylobacter 15 0.31 <0.0001 
Rotavirus + ETEC-eltB 83 0.73 0.046 
Rotavirus+ EPEC-eae 54 0.59 0.0025 
Rotavirus+Shigella 23 0.23 <0.0001 
Shigella + Astrovirus 2 0.22 0.020 
a P value by Fisher´s exact test 
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Taken together, these findings suggest that Shigella and EPEC-eae co-
infection might have a synergistic effect to  cause aggravated diarrhoea.  
We do not have any mechanistic explanation to this putative synergy. A 
possible explanation might be that, although Shigella and EPEC infec-
tions have different pathogenesis, together they might induce a more 
intense inflammatory response [159], which could result in a higher rate 
of diarrhoea than expected from the rate observed in patients with only 
either pathogen.  
 
Similar calculations to determine multiplicative interaction (potential 
synergy) between co-infecting pathogens was used by Bhavnani et al., 
whose findings indicated synergy between rotavirus and Giardia [125].  
4.1.2 Positive correlation in both patients and controls 
Positive correlation in both patients and controls were found both for 
the mere detection of, and for Ct values for ETEC-estA and ETEC-eltB 
and for EPEC-eae and EPEC-bfpA. In addition, the Ct values were 
similar, differing by less than 3.3 cycles (corresponding to < 1 log10) in 
many samples, suggesting that the target genes were likely present in the 
same bacterial strains. In samples with a greater difference in Ct the 
target genes were probably present in separate strains, each carrying 
only one of them. This use of Ct values to estimate the proportion of 
samples with typical EPEC, or with ETEC producing both toxins, is to 
our knowledge novel and represents a strategy to avoid that the tran-
sition from traditional to molecular methods leads to loss of important 
information [160].  
4.1.3 Negative associations 
As presented in table 3 and in paper I, strong negative associations 
(p<0.0001) were found only in patients, and only for rotavirus in 
combination with Shigella, norovirus GII or Campylobacter. These 
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negative associations were thus only found for pathogens that 
previously have been strongly associated with symptomatic infection [8-
11,13,78], and were from a statistical point expected. 
 
In a large study from India, negative associations were seen between 
rotavirus and Shigella, and between Vibrio cholerae and rotavirus, Shigella 
and ETEC [127]. In Chinese patients with diarrhoea, negative 
associations were observed between rotavirus and norovirus GII or 
diarrhoeagenic E. coli [126]. The interpretation of negatively associated 
pathogens differs, but could point out that these are reflections of the 
capacity of these agents to cause diarrhoea on their own.  
 
ETEC-estA and rotavirus were not negatively associated despite their 
strong association with diarrhoea. Possibly, this expected negative 
association was lacking because the two pathogens had a synergistic 
effect on symptoms. This possibility is supported by a Chinese study in 
which co-infection between rotavirus and ETEC was significantly more 
frequent in patients than in controls [161], and by an experimental study 
on pigs showing that infection with rotavirus and ETEC together 
caused much more severe histopathological changes than infection with 
rotavirus alone [162]. 
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4.2 Paper II 
This study investigated a subset of children with diarrhoea that were 
included in a study of aetiologies to gastroenteritis. Out of these 165 
children with diarrhoea, aged 1-60 months and living in a rural part of 
Zanzibar, 127 provided a follow-up sample (FU) 14 days after the first 
visit, allowing investigation of the short-term course of infection.  
4.2.1 Clearance rates 
In total, 289 agents were detected at baseline (BL) in the 127 patients 
samples and 271 agents were detected in FU samples, meaning that 
numerous polymicrobial infections were present at both time points. 
Fifty-two percent of the agents detected at BL were no longer detected 
at FU, and 49% of pathogens detected at FU were new infections. 
Detailed information about presence of each pathogen at BL and FU is 
presented in Table 1, paper II.  The clearance rates for each pathogen 
detected at BL ranged between 34% and 100% (Figure 8).  
 
 
Figure 8. Clearing rates for each individual pathogen between BL and FU.	
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Data on short-term clearance of enteric pathogens have rarely been 
reported. A study from Guinea-Bissau in agreement with our findings 
showed that 81% of ETEC infections were cleared within 2 weeks. 
Another study [156], from Bangladesh performed in 1992, with 
sampling at BL and at FU 15-17 days later, showed an overall pathogen 
clearance rate of 90% and presence of 89% new infections at FU [163]. 
In our study, Cryptosporidium had the lowest clearance rates (34%) among 
the pathogens, which is in line with other studies showing that crypto-
sporidium often is associated with extended diarrhoea [78,153,154,164].  
4.2.2 Persistent infections and sequencing 
For all pathogens detected at both BL and FU, with the exception of 
Campylobacter, the mean Ct value increased, corresponding to a decline 
of the microbial concentration (Table 4). For Campylobacter the microbial 
concentration increased, and sequencing showed that a different strain 
than at baseline was present at follow-up in 75% of cases (Table 4). 
Sequencing was also performed for norovirus GII, rotavirus and Shigella 
in samples from BL and FU that had sufficient concentration for 
sequencing (Table 5). In norovirus GII persistent infections occurred in 
13 cases, of which 11 were sequenced. One patient had norovirus GII.4 
at BL and a new infection with norovirus GII.16 at FU. In the other 
cases sequencing data indicated that the same norovirus GII strain was 
present at both occasions. The persistent norovirus GII infections indi-
cate that long-time shedding was frequent, as previously observed in 
immunocompetent [131,165] and immunosuppressed children [166-
169].  
 
Most children with putative persistent infection did not have persistent 
diarrhoea. Exceptions – with the same pathogens detected at BL and 
FU and with diarrhoea at follow-up – were one child with norovirus 
GII and one with Shigella and ETEC-eltB. In addition to these two cases, 
3 more children had recorded diarrhoea at follow-up. One child had 
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received a new infection with Shigella and another a new infection with 
astrovirus while the last child had no pathogen detected. 
 
 
Table 4. Number of persistent infections and sequencing results. 
 
 
Pathogen 
No. 
Persistent 
Ct Change 
Mean 
 
P valuea 
No. 
Sequenced 
 
BL vs. FU 
Adenovirus 14 +4.63 0.008   
Astrovirus 0     
Norovirus 13 +3.86 0.007 11 7 with GII.4 →GII.4 
3 with GII.16 →GII.16 
1 with GII.4 →GII.16 
Rotavirus 3 +12.2 0.015 3 3 with G10P[8]→G10P[8]  
Sapovirus 2     
Cryptosporidium 23 +3.09 0.0005   
Campylobacter 25 -0.02 0.98 8 2 with 1-3 nt differences 
6 with 50-102 nt differences 
ETEC-eltB 30 +3.34 0.02   
ETEC-estA 8 +3.84 0.084   
Shigella 21 +.4.78 <0.001 6 3 with 2-5 nt differences 
3 with 17-27 nt differences 
a P value by paired t test, nt = nucleotide 
4.2.3 Nutrition status and clearance 
Most of the 127 children in this study were living under poor conditions 
and the nutritional status of 124 children was calculated through anthro-
pometrical data that was recorded at baseline. The median z scores for 
weight for age, height for age, weight for height and for upper arm 
circumference for age were –1.15, –1.22, –0.88 and –1.05 respectively. 
The z scores indicated moderate wasting (z score for weight for height 
below –2) in 21% and moderate stunting (z score for height for age 
below –2) in 31%.  
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Diarrhoea, enteric infections, and malnutrition are interrelated in a com-
plex manner, in which diarrhoea may contribute to malnutrition, and 
malnutrition leads to more frequent and prolonged enteric infections 
[148,170,171]. Despite that z score for weight and height being on 
average 1 standard deviation lower than normal for the age of the 
studied children, there was no statistically significant association 
between moderate wasting and detection at baseline or with clearance, 
persistence, or new infection of any of the pathogens, as shown in detail 
for weight for height in Table 3, paper II. At baseline, the 26 children 
with moderate wasting had 2.54 agents per child, among which 67% had 
been cleared at follow-up, compared with the 2.20 per child detected 
pathogens in 98 children without wasting, among which 48% had been 
cleared at follow-up. New infections were also acquired at follow-up 
with the same rate (1.15 vs. 1.01 agents per child). 
4.2.4 Polymicrobial infections and new infections 
More than one pathogen was detected in 70% of samples at baseline, 
indicating presence of a large number of asymptomatic pathogens 
together with causative pathogen. The analysis of follow-up samples 
showed that all pathogens, both causative and non-causative were 
rapidly eradicated or reduced in number. At the same time, new infec-
tions were acquired at high rates and as shown in Figure 9, 28% of all 
children had acquired a new ETEC-eltB infection at follow-up.  
 
These findings indicate that the high rates of enteric infections among 
healthy children in low-income countries are not due to persistence, but 
probably a result of frequent transient infections, most of which are 
cleared by effective immune responses.  
 
The high clearance rates were observed in both wasted and well 
nourished children demonstrating that malnutrition had not markedly 
impaired immune clearance in these children. 
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Figure 9. Frequency of new infections at FU for each individual pathogen. 
 
In reports compiled by National Bureau of Statistics and Millennium 
Development goals 2010 in Tanzania, 60%-80% (lower frequency in 
rural areas) of the total population in Zanzibar had access to improved 
water sources but only for limited hours of the day and less than 23% 
treated the water through boiling, bleach or filter before use [172,173]. 
The lack of access to high quality water together with missing improved 
facilities, used by less than 40%, are probably the major contributing 
factors to the high exposure of pathogens showed in this study, and 
these findings suggest that improving sanitary conditions and safe water 
supply are essential for reducing diarrhoeal disease among children in 
low-income parts of the world [137,139].  
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4.3 Paper III 
Rotavirus genotyping has until today mainly been performed with 
multiplex PCR, often as a nested reaction, followed by gel 
electrophoresis discrimination based on amplicon length or by Sanger 
sequencing [20,174,175]. Compared with these methods genotyping by 
real-time PCR has several advantages, including a lower risk of contami-
nation due to the closed systems, quantification that may help to distin-
guish mixed infections, and in particular it is much less cumbersome and 
has a faster turnaround time. A few previous reports have described 
genotyping methods based on real-time PCR, including one with a sepa-
rate reverse transcriptase step, one using Luminex-based detection, and 
another melting point analysis [176-178]. Centre for Disease Control and 
Prevention (Atlanta, USA) published a multiplex real-time PCR assay in 
2016 [179]. 
 
Our plan to develop a new genotyping method was initiated as a result 
of our identification of a large number of rotavirus in the studies in 
Rwanda in 2009-2012, and our wish to genotype these strains. The 
method we developed is a triple triplex real-time PCR that is presented 
in paper III. By targeting G1, G2, G3, G4, G9, G12, P[4], P[6] and P[8] 
the method identifies the vast majority of currently circulating geno-
types. It also provides Ct values that allow deduction of probable G/P 
combinations in the samples that contain mixed infections. 
4.3.1 Genotype distribution 
The genotyping method was first applied on samples that were rotavirus 
positive in clinical diagnosis in Western Sweden during 2009-2014. Out 
of these 775 rotavirus positive samples 97.3% could be genotyped. 
G1P[8] was the most common genotype, observed in 34.9%, followed 
by G2P[4] (28.3%), G9P[8] (11.5%), G3P[8] (8.1%) and G4P[8] (7.9%). 
Rare types (1%) genotyped were four G3P[6], and one of each of 
G1P[4], G1P[6], G4P[6] and G9P[6]. Mixed infections were found in 4% 
of samples and 1.5% were partly genotyped. Additional rare genotypes 
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were found among the untypeable samples with Sanger sequencing, 
presented in paper III, Table 4.  
 
During 2010–2012, G1P[8] was the most prevalent genotype, whereas 
G2P[4] became the most common genotype in 2013 and 2014. The 
change over time in genotype distribution was related to changes in the 
number of rotavirus infections in children and elderly, as shown in 
Figure 10. The rotavirus detection frequencies within these two age 
groups varied during the five-year period. Infections in children less than 
2 years of age were more often detected 2011-2012, whereas infections 
in persons above 70 years were more common during 2011 and 2013-
2014. In children below 5 years of age G1P[8] was the most common 
genotype, being observed in 46.6 % of patients, whereas G2P[4] was the 
most common type, observed in 46.1%, in individuals older than 70 
years.   
 
 	 	
 
 
 
Figure 10. Distribution of rotavirus A genotype G1P[8] and G2P[4] (A) and the 
number of rotavirus cases in the age group < 2 and > 70 years (B) in Sweden 
during 2010-2014.  
The decline in number of rotavirus infections in children in 2013 and 
2014 when G2P[4] was more prevalent is interesting but difficult to 
explain. One possibility is that in 2011 when the number of detected 
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rotavirus was high in all age groups, and in particular in children below 2 
years of age, a large proportion of the population may have acquired 
immunity, and this might explain the fewer rotavirus infections in 
children the subsequent years in accordance with a previous report [27].  
There was a relative increase of rotavirus infections in elderly during 
2013-2014 when G2P[4] was common. This finding agrees with a study 
from Finland reporting G2P[4] to be commonly detected in elderly 
between 2013 and 2015 [180]. Outbreaks due to G2P[4] in nursing 
homes for elderly have been detected in different settings [181,182]. A 
study from Illinois reported that 17% of the elderly with G2P[4] infec-
tion during an outbreak in a retirement community were hospitalized. 
Rotavirus infections in elderly outside the retirement community were 
caused by G2P[4] in 89%, while in children this genotype was found in 
38% [182].  
 
Rotavirus infection in elderly have been reported to cause 3-18% of 
adult diarrhoea, and 2-5% of hospitalizations because of gastroenteritis 
in adults [183,184]. Due to waning immunity and risk of severe dehydra-
tion in elderly >70 years, this group has been proposed to be vaccinated 
[185] Interestingly, elderly have also been shown to indirectly benefit 
from paediatric vaccination [186].  
 
The overall genotype distribution between years and different age groups 
are described in detail in paper III. 
4.3.2 Methodological considerations 
The rotavirus concentrations in the clinical samples was high, and >75% 
had a Ct below 25 (approximately corresponding to >1 million 
copies/mL). Despite high target concentrations, there was essentially no 
signs of cross-reactivity in genotyping, and even in the samples with Ct 
values below 18, the PCR was reactive for only one G type and one P 
type. The exceptions were 12 samples with a low Ct value for both G2 
and P[4]. They were classified as G2P[4], but also showed reactivity for 
P[8], however with a Ct value at least 10 cycles higher than for P[4]. This 
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weak cross-reactivity can be understood by the relatively few nucleotide 
differences between primers and probes for the P[8] and P[4] sequences, 
as shown in Figure 1, paper III). Distinguishing these cross-reactions was 
relatively easy since they resulted in differences, in both Ct value and 
shape of amplification curves (Figure 11).  
 
In chapter 3.4, heat maps showing the degree of fit between primers and 
probes for G types or P types and Genbank sequences representing the 
monovalent Rotarix and pentavalent RotaTeq vaccines are presented. 
Based on the matching, a sample containing a Rotarix strain would be 
positive by the G1 PCR and probably also by the P[8] PCR but likely 
with a higher Ct value than for G1. Despite that general vaccination 
against rotavirus has not yet been introduced in Sweden, it is possible 
that some children had received vaccination. Among the 9 samples with 
multiple G and/or P types (Table 4, paper III), only three were from 
children in age of vaccination, and none had a the genotyping pattern 
that one would expect from a vaccine strain. Still, the possibility that 
vaccine strains can be shed in faeces up to 45 days after the first vaccine 
dose (shorter after subsequent doses) [187-189], should be kept in mind 
if the analysis is performed close in time after vaccination. 
 
 	
 
 
 
  
Figure 11. Amplification plot in log scale showing a rotavirus strain reactive for 
G2 and P[4] with a low Ct value and cross-reactive P[8] with a much higher Ct 
value and different curve appearance. 
G2 and P[4] 
P[8] 
	
 
48   MARIA ANDERSSON 	
 
4.4 Paper IV 
4.4.1 Rotavirus frequency 
In total 1639 children with diarrhoea were included during two time 
periods, before and after the introduction of rotavirus vaccination in 
Rwanda in May 2012. In children younger than 12 months rotavirus 
infections were significantly less frequent in those that were vaccinated 
than those that were not (33% vs. 47%, p=0.0003). This difference was 
however not seen in children that were 12-36 months of age, among 
whom the rate rather tended to be higher among vaccinated children 
(35% vs. 30%, p=0.08). These results show that vaccination did not 
induce an overall reduction of rotavirus in the population, but post-
poned the infections until after one year of age. This indicates that 
vaccination did not induce a lasting protection against rotavirus 
infection. The effect of vaccination was still important because older 
children, as well as those below 12 months of age, had a lower risk to 
develop severe dehydration (as discussed below). These findings agree 
with a report from Zanzibar in which the rotavirus frequency declined 
from 44% before to 28% after vaccine introduction in children below 1 
year of age [46]. Reports from other African countries [45,46,48,60,190], 
have also shown a more pronounced reduction of hospitalization due to 
rotavirus after vaccine introduction in younger children (Table 1). 
4.4.2 Genotype distribution 
The genotyping method presented in paper III was applied on 549 out of 
552 rotavirus positive samples collected in Rwanda before (n=279) and 
after vaccine introduction (n=270). The vaccination coverage in Rwanda 
during 2014 and 2015, when the samples were collected, has been 
estimated to 98% in a recent study [191]. Accordingly, in our study, 94% 
of the children with rotavirus infections presenting after vaccine 
introduction had indeed been vaccinated. 
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Genotyping was successful in 91.5% of the rotavirus positive samples. 
The observed combinations of G and P types in these samples are pre-
sented in Figure 12. The prevailing genotypes varied widely over time as 
shown in Figure 13. The most common genotypes were G2P[4] (50%) 
during 2009–2010, G9P[8] (51%) during 2011–2012, and G12P[8] (59%) 
during 2014–2015 after the rotavirus vaccination was introduced.  
 
G12P[8] was frequently detected after vaccine introduction and has been 
described as an emerging genotype [21,192-195]. Reports about this and 
other rotavirus genotypes in Sub-Saharan Africa after vaccine 
introduction are however lacking. An exception is a study from Malawi, 
which reported an increased frequency of G2P[4] after vaccine introduc-
tion [190]. Increased rates of G2P[4] has been observed also in other 
countries using Rotarix [194,196-199]. Surveillance of rotavirus in 
Australia has shown that G12P[8] has been more frequent in states using 
RotaTeq vaccination, whereas G2P[4] and G3[8] has been more frequent 
in states using Rotarix [70,200-202]. Whether these differences reflect a 
lower degree of protection towards certain genotypes or merely 
represents normal fluctuations remains to be elucidated. 
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Figure 12. The total G and P distribution in 2009-
2012, 2014 and 2015 among children below5 years 
of age in Rwanda. 
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Genotype G12P[6] has been observed in several African countries with a 
modest frequency among circulating rotavirus [69,203-205] In our study 
it was only found during 2009-2012, before introduction of the vaccine. 
G1P[8] was relatively common in 2011 (28%) and 2015 (26%), but rare 
the other years. G4P[8] and G8P[4] were found in 2014 (15% and 3%), 
but essentially absent the other years.  
 
Rare genotypes, genotype mixtures, or only either a G or a P type, were 
observed in 7-15% of the samples over the years. The very rare geno-
types, detected in only a few cases during the whole period, were 
G4P[4], G4P[6], G8P[8], G9P[6], G12P[4] and 2 G8P[6]. In total there 
were 29 mixed infections with several G and/or P types present in the 
same sample.  One sample, taken 13 days after vaccination, had a pattern 
that might represent the RotaTeq vaccine (G1, G2 and G4), but that 
sample also contained G12.   
 
In general, a low viral load likely explained failure to detect any type in 
47 samples or that only either a P or G type was detected in 28 samples. 
Exceptions were 3 samples from 2011 and 7 samples from 2014, in 
which no G type was identified despite detection of P types (6 P[6] and 4 
P[4]) with low Ct values, neither by the real-time PCR genotyping, nor 
by the primers we used in amplification before sequencing. Further 
analysis with alternative primers might identify a genotype in these cases. 
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Figure 13. Rotavirus genotype distribution in subsequent years before vaccine 
introduction 2009-2012 and after vaccine introduction in 2014-2015 in Rwanda. 
4.4.3 Infections with other pathogens 
The introduction of rotavirus vaccination had an impact also on the 
relative frequency of other pathogens in children with diarrhoea. As 
shown in Table 6, astrovirus, norovirus GI and GII, sapovirus, ETEC-
estA and EPEC-bfpA infections were significantly more common while 
Cryptosporidium infections were less frequent in the vaccinated children 
(Table 5). After vaccine introduction, Shigella infections (p=0.0002) were 
more frequent in unvaccinated children as compared with the rate before 
vaccination started, but this was likely due to the higher age. 
 
A similar increase of other pathogens after rotavirus vaccine introduc-
tion has to our knowledge not been reported earlier, but a few studies 
from USA, Canada, Finland and Nicaragua have reported norovirus to 
replace rotavirus as the leading viral cause of acute gastroenteritis in 
children [55,206-210].  
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After the introduction of vaccination, we also observed that rotavirus 
was more often detected as co-infection together with other pathogens 
(76% vs. 66%, p=0.019) and that the mean number of co-infecting 
pathogens was higher (mean 1.65 vs. 1.24, p=0.0005), in vaccinated 
children. These findings suggest that in vaccinated children rotavirus was 
often not the cause of diarrhoea, or at least not the main cause.  
 
 
Table 5. Detection frequencies before and after the introduction of 
rotavirus vaccination in Rwanda. 
 
  Before vaccine  
introduction 
After introduction,  
vaccinated 
After introduction,  
unvaccinated 
Mean age (months) 18.7  13.9 35.2 	
  n=829 n=735 p valuea  n=75 p valuea 
Rotavirus 34% (279) 34% (251) 0.87 29% (22) 0.52 
Astrovirus 4% (31) 10% (77) <0.0001 9% (7) 0.032 
Norovirus GI 2% (17) 5% (34) 0.0062 5% (4) 0.089 
Norovirus GII  9% (76) 19% (143) <0.0001 8% (6) 1 
Sapovirus 4% (33) 15% (109) <0.0001 7% (5) 0.24 
Cryptosporidium 16% (135) 10% (74) 0.0003 7% (5) 0.029 
Campylobacter 8% (69) 8% (57) 0.71 5% (4) 0.51 
ETEC-eltB 31% (254) 35% (257) 0.075 33% (25)  0.70 
ETEC-estA 17% (137) 22% (160) 0.0097 13% (10) 0.62 
EPEC-bfpA 15% (125) 23% (172) <0.0001 11% (8) 0.39 
EPEC-eae 26% (214) 28% (208) 0.28 23% (17) 0.68 
Salmonella 7% (58) 5% (36) 0.088 4% (3) 0.47 
Shigella 18% (152) 21% (152) 0.25 37% (28) 0.0002 
a By Fisher’s exact test comparing with rates before vaccination was introduced. 
 	
 
4 .  RESULTS AND DISCUSSION   53	
4.4.4 Symptoms before and after vaccine introduction 
Infants and younger children are more likely to become dehydrated due 
to lower body weight and a large turnover of water and electrolytes, 
while older children more easily handle minor fluid imbalances. The rate 
of severe dehydration in children infected with rotavirus was significantly 
(p<0.0001) lower in vaccinated than in unvaccinated children (3.6% vs. 
18.3%). These declined rates of sever dehydration was present among 
children less than 12 month as well as in children between 12 and 36 
month. In children over 36 month sever dehydration was not present, 
neither in unvaccinated or vaccinated. The lower rate of severe 
dehydration in vaccinated children with rotavirus infections could have 
two explanations. One is that the diarrhoea was caused by another, less 
virulent pathogen, the other that diarrhoea was indeed caused by rota-
virus but that the vaccine-induced immunity reduced the symptoms. 
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6. Conclusions  
Paper I 
• Polymicrobial enteric infections were very common in East African 
children with or without diarrhoea. 
• Negative associations were only found in patients, between 
pathogens known to have a strong association with diarrhoea on their 
own 
• Positive associations indicating synergistic interaction were rare.  
• Co-infection between Shigella and EPEC-eae was positively associated 
in patients but not in controls, and was also associated with more 
pronounced symptoms in children with diarrhoea, suggesting that it 
might have a synergistic effect on symptoms. 
• Ct value for estA/eltB and eae/bfpA genes in ETEC or EPEC corre-
lated in both patients and controls, allowing estimation of the 
proportion of strains that carried both or only either of these 
virulence genes. 
 
Paper II 
• Most symptomatic and asymptomatic infections were cleared within 
2 weeks, also in malnourished children.  
• Children in poor socioeconomic setting acquire new enteric infec-
tions within two weeks after gastroenteritis at a high frequency. 
• The findings show that the high frequency of enteric infections in 
these children was due to living conditions with massive exposure 
rather than to malnutrition and poor clearance due to defect immune 
responses.  
Paper III 
• The new real-time PCR genotyping assay identified a rotavirus geno-
type in 97% of all rotavirus strains in Swedish clinical samples. 
• The genotype distribution of rotavirus in Sweden was age related and 
changed over time.  
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Paper IV 
• The overall frequency of rotavirus remained high after vaccine intro-
duction in Rwanda.  
• Rotavirus infections in children below one year of age were signifi-
cantly less frequent after vaccine introduction against this virus. 
• Infections by astrovirus, norovirus GI and GII and sapovirus were 
significantly more common after rotavirus vaccine introduction. 
• Co-infection between rotavirus and other pathogens appeared more 
often after than before vaccine introduction. 
• The predominant rotavirus genotype changed over time, both before 
and after vaccine introduction. 
• Symptoms in children with rotavirus infections were milder in those 
that were vaccinated than in unvaccinated.  
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7. Concluding remarks and future 
perspective 
In agreement with previous studies we found that polymicrobial enteric 
infections are common in low-income settings. The negative associations 
between some pathogens and the rare signs of synergistic effects indicate 
that probably only one pathogen is responsible for the symptoms. 
Further studies of how enteric pathogens interact and if certain co-
infections may aggravate symptoms are however needed. In these 
studies, it is important that the statistically expected negative associations 
between pathogens have been considered, which has not been the case 
in previous studies.  
 
The high frequency of new enteric infections within two weeks after 
diarrhoea in children less than 5 years, living in poor socioeconomical 
settings, rather reflect the frequent exposition to enteric pathogens than 
an inadequate immune response. This is strengthened by the high 
clearance rates, of both the causative and co-infecting pathogen. This 
was not affected by malnutrition, which indicates an effective immune 
response rather than long duration of carriership. Overall, these findings 
emphasize the importance of continuing the work for improved water 
quality and sanitation in poor socioeconomical settings in order to 
decrease the number of diarrhoea incidences.  
 
The introduction of rotavirus vaccination in Rwanda had reduced the 
number of rotavirus infections in children less than 1 year old and the 
proportion with severe dehydration, but the number of rotavirus 
infections in all ages remained high and unchanged. This emphasizes the 
importance of continued monitoring of both rotavirus incidence and 
rotavirus genotypes, in order to fully evaluate the effect of the vaccine 
introduction. In this work, the genotyping method that we have 
developed should be very useful. 
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